A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance.

International journal of clinical practice

Volumn 60, Issue 7, 2006, Pages 847-855

  Josse, R G ^a   McGuire, A J ^a   Saal, G B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT;

COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; GLUCOSE INTOLERANCE; HUMAN; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ACARBOSE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; MASS SCREENING; RISK FACTORS; TREATMENT OUTCOME;

EID: 34247377222     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00914.x     Document Type: Review

References (55)